The Food and Drug Administration recently approved two new medical software applications as devices that help physicians assess a patient’s cognitive function following a possible concussion.
According to the FDA, the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and ImPACT Pediatric are the first such medical devices permitted for marketing in the U.S. to inform clinical decisions.
Register or login for access to this item and much more
All Health Data Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access